2025-10-23 - Analysis Report
Okay, here's an analysis of TG Therapeutics (TGTX) based on the provided data. I'll structure the report in English, provide key numbers first, and then add analysis.

## TG Therapeutics (TGTX) Analysis

**Company Overview:** TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

### 1. Performance vs. S&P 500 (VOO)

*   **TGTX Cumulative Return:** 83.60%
*   **VOO Cumulative Return:** 99.09%
*   **Absolute Divergence:** -14.0
*   **Relative Divergence:** 21.4 (Indicates TGTX's divergence from VOO is in the lower quartile of its historical range).

**Analysis:** TGTX has underperformed the S&P 500 (VOO) over the period. The relative divergence suggests this underperformance is relatively mild compared to its historical fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
|------------|---------|-------|---------|--------|--------|
| 2015-2017  | -5.0%   | 73.5% | -33.0%  | -0.0   | 1.3    |
| 2016-2018  | -12.0%  | 73.5% | -27.0%  | -0.0   | 0.6    |
| 2017-2019  | 74.0%   | 74.1% | 52.0%   | 0.0    | 1.7    |
| 2018-2020  | 316.0%  | 74.1% | 293.0%  | 0.1    | 8.1    |
| 2019-2021  | 124.0%  | 74.1% | 78.0%   | 0.3    | 3.0    |
| 2020-2022  | -71.0%  | 77.8% | -71.0%  | -0.0   | 1.8    |
| 2021-2023  | -284.0% | 77.8% | -285.0% | -1.1   | 2.7    |
| 2022-2024  | 56.0%   | 77.8% | 36.0%   | -1.0   | 4.7    |
| 2023-2025  | 84.0%   | 80.4% | 20.0%   | -0.1   | 5.5    |

**Analysis:**

*   **CAGR:**  The Compounded Annual Growth Rate shows highly variable performance over different periods, with some years showing significant growth (e.g., 2018-2020) and others sharp declines (e.g., 2021-2023).
*   **MDD:** Maximum Drawdown remains consistently high, indicating significant volatility and risk.
*   **Alpha:** Alpha is also volatile, reflecting periods of both significant outperformance (positive Alpha) and underperformance (negative Alpha) relative to the market.  Negative Alpha in recent periods suggests the company is underperforming its benchmark on a risk-adjusted basis.
*   **Beta:** Beta fluctuates around zero, with more recent periods showing negative beta. This suggests the stock's price is not strongly correlated with the broader market. A negative beta indicates that the stock tends to move in the opposite direction of the market.
*   **Cap(B):** Market Cap (in Billions) has fluctuated, generally showing growth over time, but also periods of decline, reflecting the company's volatile performance.

### 2. Recent Stock Price Movement

*   **Current Price:** 35.22
*   **Last Market Price:** 34.59
    *   **Previous Close:** 35.22
    *   **Change:** -1.79
*   **5-Day Moving Average:** 34.986
*   **20-Day Moving Average:** 35.403
*   **60-Day Moving Average:** 32.201

**Analysis:** The current price is below both the 5-day and 20-day moving averages, suggesting a short-term downward trend.  However, it's above the 60-day moving average, which indicates a potentially stronger upward trend over the longer term. The negative change in the last market session (-1.79) suggests recent selling pressure.

### 3. Technical Indicators & Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 37.99 (Approaching oversold territory but not yet there)
*   **PPO:** -0.5941 (Slightly negative, indicating a recent downward trend in price momentum)
*   **Hybrid Signal:** cash_80%_Sell 80.0% of holdings (5528 shares - Risky - MRI:0.50) (Cash Ratio: 80% on 2025-10-16)
*   **Recent Relative Divergence Change (20-day):** 0.4 (+) (Indicates short-term upward momentum in relative performance)
*   **Expected Return (%):** -105.3 (Significant underperformance compared to S&P 500 over a 2+ year investment horizon)

**Analysis:**

*   The **MRI** indicates a high investment recommendation, seemingly contradictory to other indicators. This might be due to the model's specific criteria and weighting of factors.
*   The **RSI** suggests the stock is nearing oversold conditions, potentially indicating a buying opportunity, but further confirmation is needed.
*   The **PPO** suggests slight downward momentum in price.
*   The **Hybrid Signal** suggests a strategy of selling 80% of holdings and increasing cash position to 80%, based on a "Risky" assessment (MRI: 0.50).
*   The recent increase in relative divergence and negative expected return creates conflicting signals.
*   Given the significant change in last market price, it signals bearish trend

### 4. Recent News & Significant Events

*   **Positive News Regarding BRIUMVI:** Multiple news articles highlight positive 6-year data for BRIUMVI, demonstrating high rates of freedom from disability progression in multiple sclerosis patients.
*   **Institutional Investor Activity:** News suggests institutional investors have been rewarded for their bets on TGTX.

**Analysis:** The news flow is largely positive, focusing on the long-term efficacy of BRIUMVI and institutional investor confidence. This could be a positive catalyst for the stock.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 1.78)
*   **Target Price:**
    *   **Average:** 43.57
    *   **High:** 60.00
    *   **Low:** 11.00

**Analysis:** Analyst sentiment is generally positive, with a "Buy" consensus and a significantly higher average target price than the current price. However, the wide range between the high and low target prices indicates a considerable level of uncertainty.

### 5. Recent Earnings Analysis

| 날짜       | EPS  | 매출     |
|------------|------|----------|
| 2025-08-08 | 0.19 | 0.14 B$  |
| 2025-05-09 | 0.03 | 0.12 B$  |
| 2024-11-07 | 0.03 | 0.08 B$  |
| 2024-08-09 | 0.05 | 0.07 B$  |
| 2025-08-08 | 0.05 | 0.07 B$ |

**Analysis:**

*   **EPS:** Earnings Per Share has fluctuated, with a recent spike in the latest quarter (2025-08-08).
*   **Revenue:** Revenue has generally been increasing over the periods shown, with the most recent quarter showing a significant jump to $0.14B.  The growth in revenue is a positive sign.

### 6. Financial Information:

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-06-30   | $0.14B    | 86.58%        |
| 2025-03-31   | $0.12B    | 87.14%        |
| 2024-12-31   | $0.11B    | 85.77%        |
| 2024-09-30   | $0.08B    | 88.86%        |
| 2024-06-30   | $0.07B    | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE      |
|--------------|-----------|----------|
| 2025-06-30   | $0.28B    | 10.20%   |
| 2025-03-31   | $0.24B    | 2.13%    |
| 2024-12-31   | $0.22B    | 10.49%   |
| 2024-09-30   | $0.19B    | 2.02%    |
| 2024-06-30   | $0.18B    | 3.87%    |

**Analysis:**

*   **Revenue:** Shows a consistent upward trend, indicating growing sales.
*   **Profit Margin:** Remains very high, consistently above 85%, which is impressive.
*   **Equity:**  Increasing Equity suggests the company's net worth is growing.
*   **ROE:** Return on Equity fluctuates, but shows peaks, indicating periods of strong profitability relative to equity.

### 7. Overall Analysis

TG Therapeutics (TGTX) presents a mixed picture.

*   **Positives:**
    *   Positive long-term data for BRIUMVI, a key product.
    *   Institutional investor confidence.
    *   Analyst "Buy" consensus and high target prices.
    *   Strong revenue growth and very high profit margins.
    *   Increasing Equity.
*   **Negatives:**
    *   Underperformance compared to the S&P 500.
    *   High historical volatility (high MDD).
    *   Conflicting signals from technical indicators (e.g., MRI vs. Hybrid Signal).
    *   Significantly negative expected return compared to the S&P 500 over a long-term investment horizon.
    *   Recent market price weakness.

**Conclusion:**

TGTX appears to be a high-risk, high-reward stock. The positive clinical data for BRIUMVI and strong financial performance could drive future growth. However, the stock is volatile, and recent performance has been weak. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing. The conflicting signals from the technical indicators suggest a need for caution and further analysis.
